会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Method for Treating Malignant Melanoma
    • 治疗恶性黑色素瘤的方法
    • US20090220472A1
    • 2009-09-03
    • US12158681
    • 2006-12-20
    • Ola WinqvistMagnus Thörn
    • Ola WinqvistMagnus Thörn
    • A61K35/12
    • A61K39/0011A61K38/21A61K2039/5158C12N5/0636C12N2501/23G01N2333/57
    • The present invention discloses an immunotherapeutic method for treating patients suffering from malignant melanoma, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a malignant melanoma or a metastasis arising from malignant melanoma. The present invention provides a new effective method for treating malignant melanoma and metastatic malignant melanoma, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a malignant melanoma or a metastasis there from, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes.
    • 本发明公开了一种用于治疗患有恶性黑色素瘤的患者的免疫治疗方法,其通过施用扩增的肿瘤反应性CD4 +辅助细胞和/或CD8 + T淋巴细胞,所述扩增的肿瘤反应性CD4 +辅助细胞和/或CD8 + T淋巴细胞可从排除恶性黑素瘤的一个或多个前哨淋巴结或met淋巴结或由恶性黑素瘤引起的转移 黑色素瘤 本发明提供了治疗恶性黑素瘤和转移性恶性黑素瘤的新型有效方法,其与已知治疗相关的无副作用。 该方法包括在患者中识别排出恶性黑素瘤或其中的转移的一个或多个前哨淋巴结和/或met淋巴结,切除一个或多个淋巴结,以及任选全部或部分肿瘤或转移,分离肿瘤 来自所述淋巴结的反应性T淋巴细胞,所述肿瘤反应性T淋巴细胞的体外扩增,以及由此获得的肿瘤反应性T淋巴细胞给予患者,其中T淋巴细胞是CD4 +辅助和/或CD8 + T淋巴细胞。
    • 3. 发明申请
    • Method for Treating Urinary Bladder Cancer
    • 尿膀胱癌的治疗方法
    • US20090074714A1
    • 2009-03-19
    • US12158680
    • 2006-12-20
    • Ola WinqvistMagnus Thorn
    • Ola WinqvistMagnus Thorn
    • A61K38/20A61K35/12A61K39/395
    • A61K39/0011C12N5/0636C12N2501/23C12N2501/505
    • The present invention discloses an immunotherapeutic method for treating a patient suffering from urinary bladder cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a tumour in the bladder or a metastasis arising from a tumour in the bladder The method provides a new effective method for treating urinary bladder cancer and metastatic bladder cancer, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a tumour in the bladder or a metastasis from a tumour in the bladder, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+helper and/or CD8+ T-lymphocytes.
    • 本发明公开了一种用于治疗患有膀胱癌的患者的免疫治疗方法,其通过施用扩增的肿瘤反应性CD4 +辅助细胞和/或CD8 + T淋巴细胞,所述淋巴细胞可从膀胱中的一个或多个前哨淋巴结或met淋巴结排出肿瘤或转移 由膀胱肿瘤引起的这种方法提供了一种治疗膀胱癌和转移性膀胱癌的新型有效方法,没有与已知治疗相关的副作用。 该方法包括在患者中识别排出膀胱中的肿瘤或来自膀胱中的肿瘤的转移的一个或多个哨兵和/或met淋巴结,切除一个或多个节点以及任选的全部或部分肿瘤 或转移,从所述淋巴结分离肿瘤反应性T淋巴细胞,所述肿瘤反应性T淋巴细胞的体外扩增,以及由此获得的肿瘤反应性T淋巴细胞给予患者,其中T淋巴细胞为 CD4 +辅助细胞和/或CD8 + T淋巴细胞。
    • 4. 发明申请
    • METHOD FOR EXPANSION OF TUMOUR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH SPECIFIC CANCER TYPES
    • 用于特异性癌症患者免疫的肿瘤反应性T淋巴细胞扩增的方法
    • US20090022695A1
    • 2009-01-22
    • US12147752
    • 2008-06-27
    • Ola WinqvistMagnus Thorn
    • Ola WinqvistMagnus Thorn
    • A61K35/12C12N5/08
    • A61K39/0011A61K2039/5158
    • Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and/or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.
    • 公开和描述了治疗患有肿瘤疾病的患者的方法。 可以根据本发明的方法治疗许多疾病,包括但不限于胆囊癌,肝细胞癌,卵巢癌,小肠癌,肺癌,间皮瘤,乳腺癌,肾癌,胰腺癌,前列腺癌,类癌, 平滑肌肉瘤或其转移。 提供这种治疗的一般方法可以包括:1)在患者身上识别排出赘生物的一个或多个哨兵和/或met淋巴结; 2)切除一个或多个节点,以及可选地全部或部分肿瘤或转移; 3)从所述淋巴结中分离肿瘤反应性T淋巴细胞; 4)体外扩增肿瘤反应性T淋巴细胞; 和5)将由此获得的肿瘤反应性T淋巴细胞给予患者。
    • 6. 发明授权
    • Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
    • 扩大肿瘤反应性T淋巴细胞免疫治疗癌症患者的方法
    • US08206702B2
    • 2012-06-26
    • US12158686
    • 2006-12-20
    • Ola WinqvistMagnus Thörn
    • Ola WinqvistMagnus Thörn
    • A01N63/02A61K35/02A61K35/26
    • C12N5/0636A61K2039/5158C12N5/0651
    • The present invention discloses an improved method for expansion and activation of tumor-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes, which may be used for treating and/or preventing cancer. The method provides high numbers of tumor-reactive T-lymphocytes within a short time span and the possibility of directing development of tumor-reactive CD4+ helper and/or CD8+ T-lymphocytes towards specific subpopulations. The method comprises a first phase of stimulating tumor-reactive CD4+ T helper and/or CD8+ T-lymphocytes with tumor-derived antigen together with at least one substance having agonistic activity towards the IL-2 receptor to promote survival of tumor-reactive CD4+ T helper and/or CD8+ T-lymphocytes; and a second phase of activating and promoting growth of tumor-reactive CD4+ T helper and/or CD8+ T-lymphocytes, wherein the second phase is initiated when the CD25 cell surface marker (or IL-2R marker) is down-regulated on CD4+ T helper and/or CD8+ T-lymphocytes.
    • 本发明公开了可用于治疗和/或预防癌症的肿瘤反应性淋巴细胞,特别是CD4 +辅助和/或CD8 + T淋巴细胞的扩增和活化的改进方法。 该方法在短时间内提供了大量的肿瘤反应性T淋巴细胞,以及将肿瘤反应性CD4 +辅助细胞和/或CD8 + T淋巴细胞向特定亚群发展的可能性。 该方法包括用肿瘤衍生的抗原刺激肿瘤反应性CD4 + T辅助细胞和/或CD8 + T淋巴细胞的第一阶段以及至少一种对IL-2受体具有激动作用的物质以促进肿瘤反应性CD4 + T的存活 辅助和/或CD8 + T淋巴细胞; 以及激活和促进​​肿瘤反应性CD4 + T辅助细胞和/或CD8 + T淋巴细胞生长的第二阶段,其中当CD25细胞表面标志物(或IL-2R标志物)在CD4 + T上下调时启动第二阶段 辅助和/或CD8 + T淋巴细胞。